Efficient tumor control of glioma and BrM was shown to depend on enhanced CD8+ T‐cell priming and recruitment to CNS lesions which synergized with ICB (Taggart et al,2018; Song et al,2020). The gene discussed is CD8A; the disease is central nervous system cancer.